The European Medicine Agency has recommended marketing authorization for a hybrid colchicine medicine for secondary prevention of atherothrombotic events in adults with stable coronary disease.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. If colchicine and its prospects as a COVID-19 treatment ...

In patients with stable coronary artery disease, colchicine 0.5 mg per day did not impact low-attenuation plaque volume but ...

Health insurance, The patient was treated at the hospital with the health of the insured. RECOVERY, a large, randomized clinical trial, assessed the efficacy of colchicine, a proposed treatment for ...

Anti-inflammatory oral drug colchicine improved COVID-19 outcomes for patients with relatively mild cases, according to certain topline results from the COLCORONA trial announced in a brief press ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising ...

Colchicine, a widely available gout medication, has received FDA approval to be used in low dose to prevent cardiovascular events in patients with proven coronary disease. The approval to use low dose ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Scientists in the U.S. plan to send an existing drug to COVID-19 ...

(RTTNews) - Scilex Holding Co. (SCLX) announced that FDA has approved it request for the Orphan drug designation for colchicine for the treatment of pericarditis. Pericarditis is an inflammation of ...

Gout flare in the hand of an elderly person Researchers compared the effectiveness and safety of naproxen with low-dose colchicine in the treatment of gout flares in primary care. Compared with ...